Related Experiment Video
Updated: Jul 24, 2026
Transfection, Selection, and Colony-picking of Human Induced Pluripotent Stem Cells TALEN-targeted with a GFP Gene into the AAVS1 Safe Harbor
Published on: February 1, 2015
Targetable gene delivery vectors
Abstract:
Adenoviral vectors, which have targeting ligands for tumor cells on the capsid, no natural tropism, and carry a therapeutic payload should be constructed soon and tested in pre-clinical models. Nevertheless, there are still important considerations for the design and therapeutic use of targetable vectors. Perhaps the single greatest challenge in the future, as it was in the past, will be finding ligands that have a higher apparent affinity for tumor and/or tumor endothelial cells then normal cells. However, the advent of many rapidly advancing technologies and information including the sequencing of the human genome, in vivo and in vitro phage display, rapid analysis of gene and protein expression in any context, and new cellular targets such as angiogenic endothelial cells, may provide many opportunities for the discovery of novel and useful ligands. In addition, the interests in targeting vectors are rapidly growing with new journals and meetings solely devoted to this subject increasing annually. Within the next 5 years, we should have meaningful clinical data on targetable vectors to reassess our progress.
Insights
Developing targeted adenoviral vectors for cancer therapy requires identifying specific ligands that bind tumor cells. Advances in technology offer new opportunities for discovering these crucial ligands for future clinical applications.
Area of Science:
- Biotechnology
- Gene Therapy
- Oncology
Background:
- Adenoviral vectors are being engineered with targeting ligands for tumor cells.
- These vectors lack natural tropism and carry therapeutic payloads.
- Challenges remain in designing vectors with high affinity for tumor cells over normal cells.
Purpose of the Study:
- To explore the design and therapeutic use of targetable adenoviral vectors.
- To identify novel ligands with higher affinity for tumor and/or tumor endothelial cells.
- To assess the potential of emerging technologies in ligand discovery.
Main Methods:
- Utilizing advancements like human genome sequencing.
- Employing in vivo and in vitro phage display techniques.
- Analyzing gene and protein expression for new cellular targets, including angiogenic endothelial cells.
Main Results:
- Emerging technologies provide opportunities for discovering novel and useful ligands.
- Growing interest in targeted vectors is evidenced by dedicated journals and meetings.
- Significant progress is anticipated in the next five years.
Conclusions:
- Targetable adenoviral vectors hold promise for cancer therapy.
- Continued research and technological advancements are key to overcoming design challenges.
- Meaningful clinical data on targeted vectors is expected within five years.
Related Concept Videos
01:16In-vitro Mutagenesis
00:59Gene Therapy
01:24Modified-Release Drug Delivery Systems: Site-Targeted